Seres Therapeutics (MCRB) Begins Phase 1b Trial of SER-301 for Treatment of Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Seres Therapeutics (MCRB) Begins Phase 1b Trial of SER-301 for Treatment of Ulcerative Colitis

Seres Therapeutics (MCRB) Misses Q3 EPS by 11c, Revenues Miss

November 9, 2020 7:11 AM EST

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.42 million versus the consensus estimate of $7.28 million.

Supported by our positive, highly significant SER-109 Phase 3 results, we expect SER-109 to be the first-ever microbiome therapy approved by the U.S. FDA.... More